Skip to content

8 November 2021

Aussie AI diagnostics med-tech Artrya takes heart from new UK NHS status


Artrya Salix has been accepted as an NHS supplier for artificial intelligence software.

Our SaaS product for the detection and diagnosis of coronary artery disease was announced as one of a select shortlist for the United Kingdom’s National Health Service Shared Business Services Limited Framework last month.

The Framework Agreement means 1250 hospitals and other health organisations across the UK will be able to purchase Artrya Salix with ease, simplifying procurement processes and pricing agreement. Artrya anticipates receiving the UKCA regulatory approval mid-2022, allowing commercial activity to commence.

This is another great milestone as we progress our mission to save lives from coronary artery disease through advanced detection technologies.

Artrya Salix is the only dedicated product focusing on coronary artery disease patient risk identification including the detection of vulnerable plaque and workflow optimisation.

We are listed in the ARTG in Australia, and have applied for Food and Drug Administration (FDA) regulatory clearance in the US and Health Canada clearance for the Canadian market.

Find out more about how Artrya Salix is bringing to market a new way to see cardiac health.